{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:14Z","timestamp":1794047414945,"version":"4.8.0"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>After allogeneic hematopoietic stem cell transplantation (HSCT), the emergence of circulating cytomegalovirus (CMV)- specific T cells correlates with protection from CMV reactivation, an important risk factor for non-relapse mortality. However, functional assays measuring CMV-specific cells are time-consuming and often inaccurate at early time-points. We report the results of a prospective single-center, non-interventional study that identified the enumeration of Dextramerpositive CMV-specific lymphocytes as a reliable and early predictor of viral reactivation. We longitudinally monitored 75 consecutive patients for 1 year after allogeneic HSCT (n=630 samples). The presence of \u22650.5 CMV-specific CD8+ cells\/mL at day +45 was an independent protective factor from subsequent clinically relevant reactivation in univariate (P&lt;0.01) and multivariate (P&lt;0.05) analyses. Dextramer quantification correlated with functional assays measuring interferon-\u03b3 production, and allowed earlier identification of high-risk patients. In mismatched transplants, the comparative analysis of lymphocytes restricted by shared, donor- and host-specific HLA revealed the dominant role of thymic-independent CMV-specific reconstitution. Shared and donor-restricted CMV-specific T cells reconstituted with similar kinetics in recipients of CMV-seropositive donors, while donor-restricted T-cell reconstitution from CMV-seronegative grafts was impaired, indicating that in primary immunological responses the emergence of viral-specific T cells is largely sustained by antigen encounter on host infected cells rather than by cross-priming\/presentation by non-infected donor-derived antigen-presenting cells. Multiparametric flow cytometry and high-dimensional analysis showed that shared-restricted CMV-specific lymphocytes display a more differentiated phenotype and increased persistence than donor-restricted counterparts. In this study, monitoring CMV-specific cells by Dextramer assay after allogeneic HSCT shed light on mechanisms of immune reconstitution and enabled risk stratification of patients, which could improve the clinical management of post-transplant CMV reactivations.<\/jats:p>","DOI":"10.3324\/haematol.2022.280685","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T03:54:05Z","timestamp":1665028445000},"page":"1530-1543","source":"Crossref","is-referenced-by-count":20,"title":["Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.3324","volume":"108","author":[{"given":"Elena","family":"Tassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Noviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantaleo","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Lupo-Stanghellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Doglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Abbati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Valtolina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Racca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Campodonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roee","family":"Dvir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Oltolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Vago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselotte","family":"Brix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"48266","doi-asserted-by":"crossref","unstructured":"Passweg JR, Baldomero H, Chabannon C. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021; 56(7):1651-1664.","DOI":"10.1038\/s41409-021-01227-8"},{"key":"48267","doi-asserted-by":"crossref","unstructured":"Penack O, Peczynski C, Mohty M. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020; 4(24):6283-6290.","DOI":"10.1182\/bloodadvances.2020003418"},{"key":"48268","doi-asserted-by":"crossref","unstructured":"Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011; 25(1):151-169.","DOI":"10.1016\/j.hoc.2010.11.011"},{"key":"48269","doi-asserted-by":"crossref","unstructured":"Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010; 47(1-3):65-77.","DOI":"10.1007\/s12026-009-8139-0"},{"key":"48270","doi-asserted-by":"crossref","unstructured":"Mussetti A, Greco R, Peccatori J, Corradini P. Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?. Expert Rev Hematol. 2017; 10(5):479-492.","DOI":"10.1080\/17474086.2017.1318054"},{"key":"48271","doi-asserted-by":"crossref","unstructured":"Goldsmith SR, Abid MB, Auletta JJ. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021; 137(23):3291-3305.","DOI":"10.1182\/blood.2020009362"},{"key":"48272","doi-asserted-by":"crossref","unstructured":"Oltolini C, Greco R, Galli L. Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA matching. Biol Blood Marrow Transplant. 2020; 26(6):1179-1188.","DOI":"10.1016\/j.bbmt.2020.01.013"},{"key":"48273","doi-asserted-by":"crossref","unstructured":"Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994; 83(7):1971-1979.","DOI":"10.1182\/blood.V83.7.1971.1971"},{"key":"48274","doi-asserted-by":"crossref","unstructured":"Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood. 2010; 115(19):3861-3868.","DOI":"10.1182\/blood-2009-12-234096"},{"key":"48275","doi-asserted-by":"crossref","unstructured":"Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol. 2012; 19(4):324-335.","DOI":"10.1097\/MOH.0b013e328353bc7d"},{"key":"48276","doi-asserted-by":"crossref","unstructured":"El Haddad L, Ariza-Heredia E, Shah DP. The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients. J Infect Dis. 2019; 219(6):898-907.","DOI":"10.1093\/infdis\/jiy592"},{"key":"48277","doi-asserted-by":"crossref","unstructured":"Wagner-Drouet E, Teschner D, Wolschke C. Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica. 2021; 106(2):363-374.","DOI":"10.3324\/haematol.2019.229252"},{"key":"48278","doi-asserted-by":"crossref","unstructured":"Avetisyan G, Aschan J, Hagglund H, Ringden O, Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant. 2007; 40(9):865-869.","DOI":"10.1038\/sj.bmt.1705825"},{"key":"48279","doi-asserted-by":"crossref","unstructured":"Navarro D, Amat P, de la Camara R. Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients. Open Forum Infect Dis. 2016; 3(2):ofw107.","DOI":"10.1093\/ofid\/ofw107"},{"key":"48280","doi-asserted-by":"crossref","unstructured":"Yong MK, Cameron PU, Slavin M. Identifying cytomegalovirus complications using the Quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2017; 215(11):1684-1694.","DOI":"10.1093\/infdis\/jix192"},{"key":"48281","doi-asserted-by":"crossref","unstructured":"Krawczyk A, Ackermann J, Goitowski B. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR. J Clin Virol. 2018; 99-100:61-66.","DOI":"10.1016\/j.jcv.2018.01.002"},{"key":"48282","doi-asserted-by":"crossref","unstructured":"Tey SK, Kennedy GA, Cromer D. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One. 2013; 8(10):e74744.","DOI":"10.1371\/journal.pone.0074744"},{"key":"48283","doi-asserted-by":"crossref","unstructured":"Cwynarski K, Ainsworth J, Cobbold M. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001; 97(5):1232-1240.","DOI":"10.1182\/blood.V97.5.1232"},{"key":"48284","doi-asserted-by":"crossref","unstructured":"Gratama JW, Boeckh M, Nakamura R. Immune monitoring with iTAg MHC tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood. 2010; 116(10):1655-1662.","DOI":"10.1182\/blood-2010-03-273508"},{"key":"48285","doi-asserted-by":"crossref","unstructured":"Varanasi PR, Ogonek J, Luther S. Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation. PLoS One. 2019; 14(3):e0213739.","DOI":"10.1371\/journal.pone.0213739"},{"key":"48286","doi-asserted-by":"crossref","unstructured":"Kato R, Tamaki H, Ikegame K. Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation. Ann Hematol. 2015; 94(10):1707-1715.","DOI":"10.1007\/s00277-015-2446-4"},{"key":"48287","doi-asserted-by":"crossref","unstructured":"Tario JD Jr, Chen GL, Hahn TE. Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples. Cytometry B Clin Cytom. 2015; 88(1):6-20.","DOI":"10.1002\/cyto.b.21196"},{"key":"48288","doi-asserted-by":"crossref","unstructured":"Ljungman P, de la Camara R, Robin C. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019; 19(8):e260-e272.","DOI":"10.1016\/S1473-3099(19)30107-0"},{"key":"48289","doi-asserted-by":"crossref","unstructured":"Greco R, Ciceri F, Noviello M. Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. Bone Marrow Transplant. 2018; 53(9):1201-1205.","DOI":"10.1038\/s41409-018-0167-8"},{"key":"48290","doi-asserted-by":"crossref","unstructured":"Cieri N, Greco R, Crucitti L. Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfanbased myeloablative conditioning and peripheral blood stem cells. Biol Blood Marrow Transplant. 2015; 21(8):1506-1514.","DOI":"10.1016\/j.bbmt.2015.04.025"},{"key":"48291","doi-asserted-by":"crossref","unstructured":"Greco R, Lorentino F, Morelli M. Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood. 2016; 128(11):1528-1531.","DOI":"10.1182\/blood-2016-06-723205"},{"key":"48292","doi-asserted-by":"crossref","unstructured":"Marty FM, Ljungman P, Chemaly RF. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017; 377(25):2433-2444.","DOI":"10.1056\/NEJMoa1706640"},{"key":"48293","doi-asserted-by":"crossref","unstructured":"Ljungman P, Boeckh M, Hirsch HH. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017; 64(1):87-91.","DOI":"10.1093\/cid\/ciw668"},{"key":"48294","doi-asserted-by":"crossref","unstructured":"Manfredi F, Abbati D, Cianciotti BC. Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells. Eur J Immunol. 2021; 51(8):1992-2005.","DOI":"10.1002\/eji.202049103"},{"key":"48295","doi-asserted-by":"crossref","unstructured":"Noviello M, Forcina A, Veronica V. Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall. Bone Marrow Transplant. 2015; 50(9):1262-1264.","DOI":"10.1038\/bmt.2015.132"},{"key":"48296","doi-asserted-by":"crossref","unstructured":"Divito SJ, Aasebo AT, Matos TR. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest. 2020; 130(9):4624-4636.","DOI":"10.1172\/JCI129965"},{"key":"48297","doi-asserted-by":"crossref","unstructured":"Cantisan S, Lara R, Montejo M. Pretransplant interferongamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant. 2013; 13(3):738-745.","DOI":"10.1111\/ajt.12049"},{"key":"48298","doi-asserted-by":"crossref","unstructured":"Zielinski M, Tarasewicz A, Zielinska H. CD28 positive, cytomegalovirus specific cytotoxic T lymphocytes as a novel biomarker associated with cytomegalovirus viremia in kidney allorecipients. J Clin Virol. 2016; 83:17-25.","DOI":"10.1016\/j.jcv.2016.08.290"},{"key":"48299","doi-asserted-by":"crossref","unstructured":"Pei XY, Zhao XY, Chang YJ. Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis. 2017; 216(8):945-956.","DOI":"10.1093\/infdis\/jix357"},{"key":"48300","doi-asserted-by":"crossref","unstructured":"Snyder CM, Cho KS, Bonnett EL. Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity. 2008; 29(4):650-659.","DOI":"10.1016\/j.immuni.2008.07.017"},{"key":"48301","doi-asserted-by":"crossref","unstructured":"Gabanti E, Bruno F, Lilleri D. Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients. PLoS One. 2014; 9(8):e106044.","DOI":"10.1371\/journal.pone.0106044"},{"key":"48302","doi-asserted-by":"crossref","unstructured":"Jackson SE, Sedikides GX, Mason GM, Okecha G, Wills MR. Human cytomegalovirus (HCMV)-specific CD4(+) T cells are polyfunctional and can respond to HCMV-infected dendritic cells in vitro. J Virol. 2017; 91(6):e02128-16.","DOI":"10.1128\/JVI.02128-16"},{"key":"48303","doi-asserted-by":"crossref","unstructured":"Chemaly RF, El Haddad L, Winston DJ. Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study. Clin Infect Dis. 2020; 71(9):2365-2374.","DOI":"10.1093\/cid\/ciz1210"},{"key":"48304","doi-asserted-by":"crossref","unstructured":"Oliveira G, Ruggiero E, Stanghellini MT. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Sci Transl Med. 2015; 7(317):317ra198.","DOI":"10.1126\/scitranslmed.aac8265"},{"key":"48305","doi-asserted-by":"crossref","unstructured":"Velardi E, Tsai JJ, van den Brink MRM. T cell regeneration after immunological injury. Nat Rev Immunol. 2021; 21(5):277-291.","DOI":"10.1038\/s41577-020-00457-z"},{"key":"48306","doi-asserted-by":"crossref","unstructured":"Sinzger C, Digel M, Jahn G. Cytomegalovirus cell tropism. Curr Top Microbiol Immunol. 2008; 325:63-83.","DOI":"10.1007\/978-3-540-77349-8_4"},{"key":"48307","doi-asserted-by":"crossref","unstructured":"Collin MP, Hart DN, Jackson GH. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med. 2006; 203(1):27-33.","DOI":"10.1084\/jem.20051787"},{"key":"48308","doi-asserted-by":"crossref","unstructured":"D'Souza WN, Hedrick SM. Cutting edge: latecomer CD8 T cells are imprinted with a unique differentiation program. J Immunol. 2006; 177(2):777-781.","DOI":"10.4049\/jimmunol.177.2.777"},{"key":"48309","doi-asserted-by":"crossref","unstructured":"Liu J, Chang YJ, Yan CH. Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. J Infect. 2016; 73(3):261-270.","DOI":"10.1016\/j.jinf.2016.04.033"},{"key":"48310","doi-asserted-by":"crossref","unstructured":"La Rosa C, Longmate J, Lingaraju CR. Rapid acquisition of cytomegalovirus-specific T cells with a differentiated phenotype, in nonviremic hematopoietic stem transplant recipients vaccinated with CMVPepVax. Biol Blood Marrow Transplant. 2019; 25(4):771-784.","DOI":"10.1016\/j.bbmt.2018.12.070"},{"key":"48311","doi-asserted-by":"crossref","unstructured":"Ljungman P, Schmitt M, Marty FM. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2020; 70(8):1525-1533.","DOI":"10.1093\/cid\/ciz490"},{"key":"48312","doi-asserted-by":"crossref","unstructured":"Hill JA, Zamora D, Xie H. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients. Blood Adv. 2021; 5(16):3113-3119.","DOI":"10.1182\/bloodadvances.2021004362"},{"key":"48313","doi-asserted-by":"crossref","unstructured":"Cassaniti I, Colombo AA, Bernasconi P. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transplant. 2021; 21(4):1622-1628.","DOI":"10.1111\/ajt.16450"},{"key":"48314","doi-asserted-by":"crossref","unstructured":"Sperotto A, Candoni A, Gottardi M. Cytomegalovirus prophylaxis versus pre-emptive strategy: different CD4(+) and CD8(+) T cell reconstitution after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021; 27(6):518.e1-518.e4.","DOI":"10.1016\/j.jtct.2021.03.003"},{"key":"48315","doi-asserted-by":"crossref","unstructured":"Zamora D, Duke ER, Xie H. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021; 138(1):34-43.","DOI":"10.1182\/blood.2020009396"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.280685\/74914","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.280685\/75649","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10813\/74914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:31Z","timestamp":1794045751000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.280685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.280685","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,6]]}}}